Evaluation of high‐sensitivity C‐reactive protein and uric acid in vericiguat‐treated patients with heart failure with reduced ejection fraction

AIMS: The effects of vericiguat vs. placebo on high‐sensitivity C‐reactive protein (hsCRP) and serum uric acid (SUA) were assessed in patients with heart failure with reduced ejection fraction (HFrEF) in the Phase 2 SOCRATES‐REDUCED study (NCT01951625). METHODS AND RESULTS: Changes from baseline hsC...

Descripción completa

Detalles Bibliográficos
Autores principales: Kramer, Frank, Voss, Sebastian, Roessig, Lothar, Igl, Bernd‐Wolfgang, Butler, Javed, Lam, Carolyn S.P., Maggioni, Aldo P., Shah, Sanjiv J., Pieske, Burkert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2020
Materias:
TREATMENT OF HFrEF
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687153/
https://www.ncbi.nlm.nih.gov/pubmed/32216011
http://dx.doi.org/10.1002/ejhf.1787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687153/
https://www.ncbi.nlm.nih.gov/pubmed/32216011
http://dx.doi.org/10.1002/ejhf.1787

Ejemplares similares